Dr. Xu has an M.D. from Tianjin Medical University in China and a Ph.D. in Microbiology and Molecular Genetics from Michigan State University. She completed her Clinical Molecular Genetics Fellowship at the University of Washington and is board certified by the American Board of Molecular Genetics and Genomics. Currently, Dr. Xu serves as CellNetix’s Chief Scientific Officer, where she has been instrumental in the development and implementation of their clinical molecular oncology tests, including next-generation sequencing (NGS) based oncology testing for both solid tumor and hematologic malignancies.